Receptos Inc (RCPT) 166.76 $RCPT
3 Biotech Stocks That Could Be Developing Billion Dollar Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 19, 10:07AM CDT
Billion dollar blockbuster status is the Holy Grail pursued by every drugmaker, but developing blockbuster drugs isn't easy. According to the Tufts Center for the Study of Drug Development, it costs $1.4 billion to develop and commercialize a new...
BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), GILD: 104.18 (-1.02), ACHN: 10.01 (-0.13), RCPT: 166.76 (-3.37)
Receptos Gains on Positive Phase II Data on Ozanimod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:28PM CDT
Receptos (RCPT) announced positive results from the maintenance period of the TOUCHSTONE study on ozanimod for ulcerative colitis.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), RCPT: 166.76 (-3.37), AFFX: 12.57 (-0.13)
Receptos
at Investor's Business Daily - Thu Apr 16, 5:55PM CDT
Receptos (RCPT) reported positive phase-2 study results for ozanimod, its lead drug candidate for ulcerative colitis, meeting all 6 of its primary endpoints for improving the chronic bowel disease after 32 weeks of maintenance. Shares rose 6.1% to...
RCPT: 166.76 (-3.37)
Receptos MS Drug Succeeds Against Ulcerative Colitis
at Investor's Business Daily - Thu Apr 16, 9:50AM CDT
Biotech Receptos (RCPT) reported positive midstage trial results for its lead drug candidate for ulcerative colitis Thursday, sending the stock up as much as 7% in early trading. Receptos said that the phase-two study, called Touchstone, met all six...
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), RCPT: 166.76 (-3.37), ABBV: 64.52 (+0.91), NVS: 103.45 (-0.62)
Receptos ulcerative colitis candidate successful in Phase 2 study
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 9:24AM CDT
RCPT: 166.76 (-3.37)
Receptos Reports Positive Results for the Maintenance Period of the Phase 2 TOUCHSTONE Trial of Ozanimod in Ulcerative Colitis
GlobeNewswire - Thu Apr 16, 7:05AM CDT
- Study met all efficacy endpoints with statistical significance for patients on 1 mg dose after 32 weeks of treatment -
RCPT: 166.76 (-3.37)
Be Careful Of The Sand Fracking Business - Cramer's Lightning Round (4/13/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Apr 14, 4:44AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 13. Bullish Calls: TG Therapeutics (NASDAQ: TGTX ): "Why don't we buy more? I thought Mike Weiss was very convincing when we had him on. I...
PSX: 80.92 (+1.42), ZIOP: 10.88 (+0.03), ADXS: 22.18 (+0.10), LMT: 197.63 (+1.34), BX: 41.76 (+0.04), EMES: 51.50 (+0.20), NOC: 162.08 (-0.41), TGTX: 16.39 (-0.18), SFL: 15.71 (+0.24), FRT: 140.45 (+0.24), KKR: 23.37 (+0.21), O: 49.52 (+0.16), VTR: 72.71 (-0.08), PBR: 8.93 (+0.35), RDS.B: 63.47 (+0.02), RDS.A: 62.36 (-0.06), EOG: 97.70 (+1.11), RCPT: 166.76 (-3.37), NAO: 10.01 (-0.07), OA: 74.50 (+0.12), RGR: 53.67 (+0.12), UNP: 110.73 (+1.23), STO: 19.34 (-0.04)
Jim Cramer's 'Mad Money' Recap: Don't Leave Gains on the Table
at The Street - Mon Apr 13, 7:19PM CDT
Using traditional analysis, investors might think Netflix is ridiculously expensive compared to where shares traded just a few months or years ago. They'd be wrong, Cramer says.
EMES: 51.50 (+0.20), BX: 41.76 (+0.04), AWAY: 32.27 (+0.76), NOC: 162.08 (-0.41), SFL: 15.71 (+0.24), KKR: 23.37 (+0.21), O: 49.52 (+0.16), VTR: 72.71 (-0.08), CTXS: 64.77 (+0.55), INFA: 47.92 (-0.03), EOG: 97.70 (+1.11), RCPT: 166.76 (-3.37), TWTR: 51.73 (+0.41), RGR: 53.67 (+0.12), CSCO: 28.62 (-0.07), PSX: 80.92 (+1.42), ADXS: 22.18 (+0.10), TGTX: 16.39 (-0.18), DISCA: 33.53 (+0.05), FRT: 140.45 (+0.24), NFLX: 557.68 (-2.76), PSG: 20.47 (+0.07), BLKB: 50.37 (+0.31), RVBD: 20.94 (+0.01), RHT: 75.76 (+0.54), STO: 19.34 (-0.04), CBS: 61.57 (+0.09)
Biotech Stock Mailbag: Biogen's Alzheimer's Update, Celgene Patent Worries, Receptos, MannKind
at The Street - Fri Apr 10, 5:01AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BIIB: 423.57 (+1.46), SNSS: 2.57 (-0.11), RCPT: 166.76 (-3.37), MNKD: 4.90 (-0.09), CELG: 115.54 (+0.72)
Stay Away From 3D Printing - Cramer's Lightning Round (4/8/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Apr 09, 5:09AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, April 8. Bullish Calls: Global Payments (NYSE: GPN ): "It's one of the few upside surprises we have seen so far in 2015. When they are up $6 like...
FSLR: 63.88 (+0.77), VIPS: 29.55 (-0.43), PXD: 172.93 (-0.64), GPN: 101.87 (+0.24), DDD: 30.55 (-0.61), FCX: 20.57 (+0.34), RCPT: 166.76 (-3.37), GOOGL: 549.18 (+6.26), MBT: 11.32 (-0.16), CSIQ: 36.24 (+0.39), GOOG: 539.36 (+5.39), HPQ: 33.51 (+0.30)
'Mad Money' Lightning Round: I'm Not Betting Against Google
at The Street - Thu Apr 09, 5:00AM CDT
Cramer is staying away from 3D Systems, Freeport-McMoRan and Mobile Telesystems but he does like Receptos.
VIPS: 29.55 (-0.43), FSLR: 63.88 (+0.77), PXD: 172.93 (-0.64), GPN: 101.87 (+0.24), DDD: 30.55 (-0.61), RCPT: 166.76 (-3.37), FCS: 19.64 (-0.12), MBT: 11.32 (-0.16), CSIQ: 36.24 (+0.39), GOGL: 5.39 (-0.28)
Jim Cramer's 'Mad Money' Recap: Really, Cheaper Oil Is Good for Stocks
at The Street - Wed Apr 08, 7:21PM CDT
The market got a gift today, says Cramer. So why were investors heading for the hills?
KMI: 44.07 (+0.46), VIPS: 29.55 (-0.43), F: 15.91 (+0.09), PRGO: 201.50 (+8.68), CCL: 46.62 (+0.03), UTX: 116.96 (+0.01), M: 67.00 (-0.03), FCS: 19.64 (-0.12), MBT: 11.32 (-0.16), CSIQ: 36.24 (+0.39), SLB: 92.16 (+0.87), LUV: 42.85 (-0.18), SAVE: 77.25 (+0.19), SONC: 30.75 (+0.14), PLCE: 62.17 (-0.18), EOG: 97.70 (+1.11), RCPT: 166.76 (-3.37), AAPL: 128.62 (+1.71), HD: 112.99 (-0.18), KR: 70.39 (-1.44), SWKS: 96.83 (+1.41), FB: 84.63 (+1.01), DDD: 30.55 (-0.61), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), BMY: 66.60 (-0.21), FRGI: 59.39 (-0.22), GOGL: 5.39 (-0.28), FSLR: 63.88 (+0.77), PXD: 172.93 (-0.64), GPN: 101.87 (+0.24), GILD: 104.18 (-1.02), TEVA: 63.01 (-1.15), WEN: 10.44 (unch)
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 08, 1:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ASPS: 18.07 (+1.32), AKAO: 6.21 (-0.50), ZSAN: 8.87 (-0.18), OCUL: 25.90 (-0.05), CACQ: 6.05 (-0.23), VBFC: 19.86 (-0.12), FLML: 15.84 (-0.33), STRS: 14.22 (+0.22), IIIN: 21.41 (+0.20), ANGI: 6.46 (+0.31), RCPT: 166.76 (-3.37), CBMG: 32.14 (+2.21), SCC.TO: 9.51 (-0.43), SRSC: 7.81 (-0.15)
Receptos (RCPT) Marked As A Dead Cat Bounce Stock
at The Street - Wed Apr 08, 8:54AM CDT
Trade-Ideas LLC identified Receptos (RCPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
RCPT: 166.76 (-3.37)
Weak On High Volume: Receptos (RCPT)
at The Street - Mon Apr 06, 9:08AM CDT
Trade-Ideas LLC identified Receptos (RCPT) as a weak on high relative volume candidate
RCPT: 166.76 (-3.37)
Receptos: Unleashing The Beast
DoconStocks - at Seeking Alpha - Thu Apr 02, 12:02PM CDT
RCPT: 166.76 (-3.37), NVS: 103.45 (-0.62)
Receptos, Inc. (RCPT) in Focus: Stock Jumps 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 8:21AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as the company saw its shares rise over 5% on the day.
ARQL: 2.11 (-0.03), RCPT: 166.76 (-3.37)
Why Receptos, Inc. Shares Soared Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 01, 4:25PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Receptos surged by as much...
BIIB: 423.57 (+1.46), RCPT: 166.76 (-3.37)
Receptos making late move on take out rumor
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 2:46PM CDT
RCPT: 166.76 (-3.37)
3 Biotech Stocks That Could Be Developing Billion Dollar Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 19, 10:07AM CDT
Billion dollar blockbuster status is the Holy Grail pursued by every drugmaker, but developing blockbuster drugs isn't easy. According to the Tufts Center for the Study of Drug Development, it costs $1.4 billion to develop and commercialize a new...
BIIB: 423.57 (+1.46), ESPR: 100.53 (-2.60), GILD: 104.18 (-1.02), ACHN: 10.01 (-0.13), RCPT: 166.76 (-3.37)
Receptos Gains on Positive Phase II Data on Ozanimod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:28PM CDT
Receptos (RCPT) announced positive results from the maintenance period of the TOUCHSTONE study on ozanimod for ulcerative colitis.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), RCPT: 166.76 (-3.37), AFFX: 12.57 (-0.13)
Receptos
at Investor's Business Daily - Thu Apr 16, 5:55PM CDT
Receptos (RCPT) reported positive phase-2 study results for ozanimod, its lead drug candidate for ulcerative colitis, meeting all 6 of its primary endpoints for improving the chronic bowel disease after 32 weeks of maintenance. Shares rose 6.1% to...
RCPT: 166.76 (-3.37)
Receptos MS Drug Succeeds Against Ulcerative Colitis
at Investor's Business Daily - Thu Apr 16, 9:50AM CDT
Biotech Receptos (RCPT) reported positive midstage trial results for its lead drug candidate for ulcerative colitis Thursday, sending the stock up as much as 7% in early trading. Receptos said that the phase-two study, called Touchstone, met all six...
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), RCPT: 166.76 (-3.37), ABBV: 64.52 (+0.91), NVS: 103.45 (-0.62)
Receptos ulcerative colitis candidate successful in Phase 2 study
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 9:24AM CDT
RCPT: 166.76 (-3.37)
Receptos Reports Positive Results for the Maintenance Period of the Phase 2 TOUCHSTONE Trial of Ozanimod in Ulcerative Colitis
GlobeNewswire - Thu Apr 16, 7:05AM CDT
- Study met all efficacy endpoints with statistical significance for patients on 1 mg dose after 32 weeks of treatment -
RCPT: 166.76 (-3.37)
Be Careful Of The Sand Fracking Business - Cramer's Lightning Round (4/13/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Apr 14, 4:44AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, April 13. Bullish Calls: TG Therapeutics (NASDAQ: TGTX ): "Why don't we buy more? I thought Mike Weiss was very convincing when we had him on. I...
PSX: 80.92 (+1.42), ZIOP: 10.88 (+0.03), ADXS: 22.18 (+0.10), LMT: 197.63 (+1.34), BX: 41.76 (+0.04), EMES: 51.50 (+0.20), NOC: 162.08 (-0.41), TGTX: 16.39 (-0.18), SFL: 15.71 (+0.24), FRT: 140.45 (+0.24), KKR: 23.37 (+0.21), O: 49.52 (+0.16), VTR: 72.71 (-0.08), PBR: 8.93 (+0.35), RDS.B: 63.47 (+0.02), RDS.A: 62.36 (-0.06), EOG: 97.70 (+1.11), RCPT: 166.76 (-3.37), NAO: 10.01 (-0.07), OA: 74.50 (+0.12), RGR: 53.67 (+0.12), UNP: 110.73 (+1.23), STO: 19.34 (-0.04)
Jim Cramer's 'Mad Money' Recap: Don't Leave Gains on the Table
at The Street - Mon Apr 13, 7:19PM CDT
Using traditional analysis, investors might think Netflix is ridiculously expensive compared to where shares traded just a few months or years ago. They'd be wrong, Cramer says.
EMES: 51.50 (+0.20), BX: 41.76 (+0.04), AWAY: 32.27 (+0.76), NOC: 162.08 (-0.41), SFL: 15.71 (+0.24), KKR: 23.37 (+0.21), O: 49.52 (+0.16), VTR: 72.71 (-0.08), CTXS: 64.77 (+0.55), INFA: 47.92 (-0.03), EOG: 97.70 (+1.11), RCPT: 166.76 (-3.37), TWTR: 51.73 (+0.41), RGR: 53.67 (+0.12), CSCO: 28.62 (-0.07), PSX: 80.92 (+1.42), ADXS: 22.18 (+0.10), TGTX: 16.39 (-0.18), DISCA: 33.53 (+0.05), FRT: 140.45 (+0.24), NFLX: 557.68 (-2.76), PSG: 20.47 (+0.07), BLKB: 50.37 (+0.31), RVBD: 20.94 (+0.01), RHT: 75.76 (+0.54), STO: 19.34 (-0.04), CBS: 61.57 (+0.09)
Biotech Stock Mailbag: Biogen's Alzheimer's Update, Celgene Patent Worries, Receptos, MannKind
at The Street - Fri Apr 10, 5:01AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BIIB: 423.57 (+1.46), SNSS: 2.57 (-0.11), RCPT: 166.76 (-3.37), MNKD: 4.90 (-0.09), CELG: 115.54 (+0.72)
Stay Away From 3D Printing - Cramer's Lightning Round (4/8/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Apr 09, 5:09AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, April 8. Bullish Calls: Global Payments (NYSE: GPN ): "It's one of the few upside surprises we have seen so far in 2015. When they are up $6 like...
FSLR: 63.88 (+0.77), VIPS: 29.55 (-0.43), PXD: 172.93 (-0.64), GPN: 101.87 (+0.24), DDD: 30.55 (-0.61), FCX: 20.57 (+0.34), RCPT: 166.76 (-3.37), GOOGL: 549.18 (+6.26), MBT: 11.32 (-0.16), CSIQ: 36.24 (+0.39), GOOG: 539.36 (+5.39), HPQ: 33.51 (+0.30)
'Mad Money' Lightning Round: I'm Not Betting Against Google
at The Street - Thu Apr 09, 5:00AM CDT
Cramer is staying away from 3D Systems, Freeport-McMoRan and Mobile Telesystems but he does like Receptos.
VIPS: 29.55 (-0.43), FSLR: 63.88 (+0.77), PXD: 172.93 (-0.64), GPN: 101.87 (+0.24), DDD: 30.55 (-0.61), RCPT: 166.76 (-3.37), FCS: 19.64 (-0.12), MBT: 11.32 (-0.16), CSIQ: 36.24 (+0.39), GOGL: 5.39 (-0.28)
Jim Cramer's 'Mad Money' Recap: Really, Cheaper Oil Is Good for Stocks
at The Street - Wed Apr 08, 7:21PM CDT
The market got a gift today, says Cramer. So why were investors heading for the hills?
KMI: 44.07 (+0.46), VIPS: 29.55 (-0.43), F: 15.91 (+0.09), PRGO: 201.50 (+8.68), CCL: 46.62 (+0.03), UTX: 116.96 (+0.01), M: 67.00 (-0.03), FCS: 19.64 (-0.12), MBT: 11.32 (-0.16), CSIQ: 36.24 (+0.39), SLB: 92.16 (+0.87), LUV: 42.85 (-0.18), SAVE: 77.25 (+0.19), SONC: 30.75 (+0.14), PLCE: 62.17 (-0.18), EOG: 97.70 (+1.11), RCPT: 166.76 (-3.37), AAPL: 128.62 (+1.71), HD: 112.99 (-0.18), KR: 70.39 (-1.44), SWKS: 96.83 (+1.41), FB: 84.63 (+1.01), DDD: 30.55 (-0.61), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), BMY: 66.60 (-0.21), FRGI: 59.39 (-0.22), GOGL: 5.39 (-0.28), FSLR: 63.88 (+0.77), PXD: 172.93 (-0.64), GPN: 101.87 (+0.24), GILD: 104.18 (-1.02), TEVA: 63.01 (-1.15), WEN: 10.44 (unch)
Nasdaq stocks posting largest percentage decreases
AP - Wed Apr 08, 1:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ASPS: 18.07 (+1.32), AKAO: 6.21 (-0.50), ZSAN: 8.87 (-0.18), OCUL: 25.90 (-0.05), CACQ: 6.05 (-0.23), VBFC: 19.86 (-0.12), FLML: 15.84 (-0.33), STRS: 14.22 (+0.22), IIIN: 21.41 (+0.20), ANGI: 6.46 (+0.31), RCPT: 166.76 (-3.37), CBMG: 32.14 (+2.21), SCC.TO: 9.51 (-0.43), SRSC: 7.81 (-0.15)
Receptos (RCPT) Marked As A Dead Cat Bounce Stock
at The Street - Wed Apr 08, 8:54AM CDT
Trade-Ideas LLC identified Receptos (RCPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
RCPT: 166.76 (-3.37)
Weak On High Volume: Receptos (RCPT)
at The Street - Mon Apr 06, 9:08AM CDT
Trade-Ideas LLC identified Receptos (RCPT) as a weak on high relative volume candidate
RCPT: 166.76 (-3.37)
Receptos: Unleashing The Beast
DoconStocks - at Seeking Alpha - Thu Apr 02, 12:02PM CDT
RCPT: 166.76 (-3.37), NVS: 103.45 (-0.62)
Receptos, Inc. (RCPT) in Focus: Stock Jumps 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 8:21AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as the company saw its shares rise over 5% on the day.
ARQL: 2.11 (-0.03), RCPT: 166.76 (-3.37)
Why Receptos, Inc. Shares Soared Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 01, 4:25PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Receptos surged by as much...
BIIB: 423.57 (+1.46), RCPT: 166.76 (-3.37)
Receptos making late move on take out rumor
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 2:46PM CDT
RCPT: 166.76 (-3.37)
